Literature DB >> 24687918

Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases.

Yataro Yoshida1, Shigeru Oguma, Hitoshi Ohno, Yukiharu Nakabo, Tatsuya Katsurada, Masahiro Kawahara, Hiroshi Kawabata.   

Abstract

We report a series of 14 patients with myelodysplastic syndrome (MDS) accompanied by a monoclonal gammopathy unrelated to therapy. Twelve of these had monoclonal gammopathy of undermined significance (MGUS) and two had smoldering multiple myeloma. These cases represent 10.2 % of all MDS cases seen at our institution over a 14-year period (January 2000 to December 2013). The incidence of MGUS was determined to be significantly higher in MDS than in age-matched concurrent controls by χ(2) test. Absence of prior chemotherapy and simultaneous presentation of MDS and MGUS in most cases suggest true co-occurrence of the two disorders. MGUS was found in all WHO subtypes of MDS with a wide range of risk factors. However, 11 out of the 12 MDS cases accompanied with MGUS had relatively low karyotypic risks. In addition, serum M protein levels remained largely unchanged in 4 cases of MGUS for which serial determinations were performed. These findings indicate that MGUS may not affect the prognosis of MDS.

Entities:  

Mesh:

Year:  2014        PMID: 24687918     DOI: 10.1007/s12185-014-1570-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

Review 1.  Immunologic abnormalities in myelodysplastic syndromes.

Authors:  T Hamblin
Journal:  Hematol Oncol Clin North Am       Date:  1992-06       Impact factor: 3.722

2.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

3.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

Authors:  Luca Malcovati; Matteo Giovanni Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Marina Boni; Erica Travaglino; Francesco Passamonti; Luca Arcaini; Margherita Maffioli; Paolo Bernasconi; Mario Lazzarino; Mario Cazzola
Journal:  J Clin Oncol       Date:  2005-09-26       Impact factor: 44.544

4.  Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).

Authors:  Sham Mailankody; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Neha Korde; Magnus Bjorkholm; Lynn R Goldin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

Review 5.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

6.  Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients.

Authors:  L E Roeker; D R Larson; R A Kyle; S Kumar; A Dispenzieri; S V Rajkumar
Journal:  Leukemia       Date:  2013-02-05       Impact factor: 11.528

Review 7.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

8.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

9.  Immunological abnormalities in myelodysplastic syndromes. II. Coexistent lymphoid or plasma cell neoplasms: a report of 20 cases unrelated to chemotherapy.

Authors:  J A Copplestone; G J Mufti; T J Hamblin; D G Oscier
Journal:  Br J Haematol       Date:  1986-05       Impact factor: 6.998

Review 10.  Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.

Authors:  Jyoti Malhotra; Marina Kremyanskaya; Emily Schorr; Ronald Hoffman; John Mascarenhas
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09-30
  10 in total
  4 in total

1.  Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome.

Authors:  T Nishihori; R Komrokji; K Shain; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2014-10-20       Impact factor: 5.483

2.  A case of simultaneous presentation of symptomatic PCM and MDS unrelated to prior chemotherapy.

Authors:  Hyerim Kim; Sang Hyuk Park; Eun Yup Lee; Moo-Kon Song
Journal:  Blood Res       Date:  2015-09-22

Review 3.  Myelodysplastic syndromes: moving towards personalized management.

Authors:  Eva Hellström-Lindberg; Magnus Tobiasson; Peter Greenberg
Journal:  Haematologica       Date:  2020-05-21       Impact factor: 9.941

4.  Co-occurrence of myeloid neoplasm and plasma cell neoplasm.

Authors:  Husam Jum'ah; Yan Wang; Salman Ayub
Journal:  Autops Case Rep       Date:  2022-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.